Home >> Tag Archives: MDxHealth—

Tag Archives: MDxHealth—

SelectMDx cost-effective in four European countries

October 2018—MDxHealth announced that a study validating the cost-effectiveness of Select­MDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases. The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen.

Read More »

Study: SelectMDx cost-effective in four European countries

Aug. 30, 2018—MDxHealth announced that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases (Govers TM, et al. Epub ahead of print Aug. 20, 2018. doi:10.1038/s41391-018-0076-3). The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a ...

Read More »

ConfirmMDx for Prostate Cancer gets final LCD

July 23, 2018—MDxHealth announced that Medicare administrative contractor Palmetto GBA has issued a positive final local coverage determination to expand Medicare coverage of the ConfirmMDx for Prostate Cancer test. The final LCD, which expands Medicare coverage to all providers, will be effective Sept. 3. The prior LCD, in 2014, limited coverage to only those providers enrolled in a certification and training ...

Read More »

ConfirmMDx included in EAU guidelines

June 2018—MDxHealth announced that its ConfirmMDx is included in the 2018 European Association of Urology guidelines. Inclusion in the guidelines will facilitate adoption of the test in EU member state-specific guidelines, and the company will pursue CE marking of the test.

Read More »

MDxHealth collaborations, 8/17

August 2017—MDxHealth has signed an exclusive licensing deal with Ghent University, Belgium, for its proprietary molecular diagnostic visualization technology that will allow the visual detection of epigenetic changes associated with cancer in tissue and liquid specimens.

Read More »

Study of clinical utility of prostate cancer test, 7/17

July 2017—MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association annual meeting in Boston.

Read More »

Medi-Cal OKs ConfirmMDx as in-network test

Sept. 26, 2016—MDxHealth announced that its molecular prostate cancer test has been made available as an in-network benefit under the California Medical Assistance Program. The program, known as Medi-Cal, is the state-run Medicaid program and—with nearly 12 million enrollees—is the largest state-run public health program in the United States. The agreement extends access to the test, ConfirmMDx for Prostate Cancer, ...

Read More »

Journal editorial backs prostate cancer liquid biopsy

Sept. 8, 2016—MDxHealth cited the publication of an editorial in the journal European Urology that supports the integration of SelectMDx liquid biopsy test results into established clinical algorithms to improve the detection of high-risk prostate cancer. “This editorial recognizes SelectMDx as a valuable molecular diagnostic test for the identification of men at risk for aggressive, potentially lethal prostate cancer, improving ...

Read More »
X